免疫检查点抑制剂在胆管癌中的当前进展与未来展望
Current Progress and Future Perspectives of Immune Checkpoint Inhibitors in Biliary Tract Cancer.
作者信息
Seesaha Poshita-Kumari, Wang Kang-Xin, Wang Guo-Qun, Cui Ting-Yun, Zhao Feng-Jiao, Pan Lan-Lan, Li Xiang-Cheng, Shu Yong-Qian, Chen Xiao-Feng
机构信息
Department of Oncology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, 210029, People's Republic of China.
Department of Oncology, Pukou Branch Hospital of Jiangsu Province Hospital (Nanjing Pukou Central Hospital), Nanjing, 211800, People's Republic of China.
出版信息
Onco Targets Ther. 2021 Mar 12;14:1873-1882. doi: 10.2147/OTT.S269671. eCollection 2021.
Abstract
Biliary tract cancer (BTC) is an uncommon and aggressive neoplasm, with most patients presenting in an advanced stage. Systemic chemotherapy is the limited treatment available but is unsatisfactory, while targeted therapy is still awaiting validation from clinical trials. Given the potential effect of immune checkpoint inhibitors (ICIs) in the treatment of BTC, this review aims to summarize the evidence-based benefits and predictive biomarkers for using inhibitors of cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) ligand, or programmed cell death protein-1 and its ligand (PD-1 and PD-L1) as monotherapy or combined with other anti-tumor therapies, while also pointing out certain pitfalls with the use of ICIs which need to be addressed.
摘要
胆管癌（BTC）是一种罕见且侵袭性强的肿瘤，大多数患者就诊时已处于晚期。全身化疗是现有的有限治疗手段，但效果不尽人意，而靶向治疗仍有待临床试验验证。鉴于免疫检查点抑制剂（ICI）在胆管癌治疗中的潜在作用，本综述旨在总结使用细胞毒性T淋巴细胞相关蛋白4（CTLA-4）配体抑制剂、程序性细胞死亡蛋白1及其配体（PD-1和PD-L1）抑制剂作为单药治疗或与其他抗肿瘤疗法联合使用的循证获益及预测生物标志物，同时也指出使用ICI时需要解决的某些问题。
相似文献
1
Current Progress and Future Perspectives of Immune Checkpoint Inhibitors in Biliary Tract Cancer.免疫检查点抑制剂在胆管癌中的当前进展与未来展望
Onco Targets Ther. 2021 Mar 12;14:1873-1882. doi: 10.2147/OTT.S269671. eCollection 2021.
2
PD-L1, TMB, MSI, and Other Predictors of Response to Immune Checkpoint Inhibitors in Biliary Tract Cancer.PD-L1、肿瘤突变负荷、微卫星不稳定性及其他胆管癌中免疫检查点抑制剂反应的预测指标
Cancers (Basel). 2021 Feb 1;13(3):558. doi: 10.3390/cancers13030558.
3
PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.PD-1/PD-L1 阻断疗法在晚期非小细胞肺癌中的应用：现状与未来方向。
Oncologist. 2019 Feb;24(Suppl 1):S31-S41. doi: 10.1634/theoncologist.2019-IO-S1-s05.
4
Expression of PD-L1 as a predictive marker of sensitivity to immune checkpoint inhibitors in patients with advanced biliary tract cancer.程序性死亡受体配体1（PD-L1）的表达作为晚期胆管癌患者对免疫检查点抑制剂敏感性的预测标志物。
Therap Adv Gastroenterol. 2022 Aug 16;15:17562848221117638. doi: 10.1177/17562848221117638. eCollection 2022.
5
Recent Advances in Immunotherapy for Advanced Biliary Tract Cancer.免疫治疗在晚期胆道癌中的最新进展。
Curr Treat Options Oncol. 2024 Aug;25(8):1089-1111. doi: 10.1007/s11864-024-01243-y. Epub 2024 Jul 27.
6
Combination therapy with PD-1 or PD-L1 inhibitors for cancer.PD-1 或 PD-L1 抑制剂联合治疗癌症。
Int J Clin Oncol. 2020 May;25(5):818-830. doi: 10.1007/s10147-019-01548-1. Epub 2019 Sep 23.
7
Targeting PD-1/PD-L1 in biliary tract cancer: role and available data.靶向程序性死亡蛋白1/程序性死亡蛋白配体1在胆管癌中的作用及现有数据
Immunotherapy. 2023 May;15(7):517-530. doi: 10.2217/imt-2022-0190. Epub 2023 Apr 3.
8
Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC).非小细胞肺癌（NSCLC）中的免疫检查点抑制剂（ICIs）。
J UOEH. 2018;40(2):173-189. doi: 10.7888/juoeh.40.173.
9
The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.下一代免疫检查点抑制剂：黑色素瘤中的PD-1/PD-L1阻断
Clin Ther. 2015 Apr 1;37(4):764-82. doi: 10.1016/j.clinthera.2015.02.018. Epub 2015 Mar 29.
10
Recent advances of immunotherapy for biliary tract cancer.免疫治疗在胆管癌中的最新进展。
Expert Rev Gastroenterol Hepatol. 2021 May;15(5):527-536. doi: 10.1080/17474124.2021.1853527. Epub 2021 Jan 8.
引用本文的文献
1
Hepatic artery infusion chemotherapy plus an immune checkpoint inhibitor and lenvatinib for the treatment of biliary tract carcinoma.肝动脉灌注化疗联合免疫检查点抑制剂及乐伐替尼治疗胆管癌。
World J Surg Oncol. 2025 Jun 13;23(1):233. doi: 10.1186/s12957-025-03882-3.
2
Comprehensive clinical and genetic characterization of hyperprogressive biliary tract cancer during PD-1 blockade monotherapy: case report and literature review.PD-1阻断单药治疗期间超进展性胆管癌的综合临床和基因特征：病例报告及文献综述
BMC Med Genomics. 2025 Mar 14;18(1):52. doi: 10.1186/s12920-025-02097-5.
3
Clinical and biomarker analyses of sintilimab plus gemcitabine and cisplatin as first-line treatment for patients with advanced biliary tract cancer.信迪利单抗联合吉西他滨和顺铂一线治疗晚期胆道癌患者的临床和生物标志物分析。
Nat Commun. 2023 Mar 11;14(1):1340. doi: 10.1038/s41467-023-37030-w.
4
Immune checkpoint inhibitors plus capecitabine and oxaliplatin in unresectable or advanced biliary tract cancer patients: A retrospective study.免疫检查点抑制剂联合卡培他滨和奥沙利铂治疗不可切除或晚期胆管癌患者：一项回顾性研究。
Front Oncol. 2022 Oct 6;12:965711. doi: 10.3389/fonc.2022.965711. eCollection 2022.
5
Immune-related RNA signature predicts outcome of PD-1 inhibitor-combined GEMCIS therapy in advanced intrahepatic cholangiocarcinoma.免疫相关 RNA 特征预测 PD-1 抑制剂联合 GEMCIS 治疗晚期肝内胆管细胞癌的疗效。
Front Immunol. 2022 Sep 9;13:943066. doi: 10.3389/fimmu.2022.943066. eCollection 2022.
6
Current options and future directions of systemic therapy for advanced biliary tract cancer.晚期胆管癌全身治疗的当前选择与未来方向
Explor Target Antitumor Ther. 2021;2(5):416-433. doi: 10.37349/etat.2021.00054. Epub 2021 Oct 31.
7
Genomic alterations in biliary tract cancer predict prognosis and immunotherapy outcomes.胆管癌中的基因组改变可预测预后和免疫治疗结果。
J Immunother Cancer. 2021 Nov;9(11). doi: 10.1136/jitc-2021-003214.
本文引用的文献
1
Current and novel therapeutic opportunities for systemic therapy in biliary cancer.当前和新型的系统治疗在胆管癌中的治疗机会。
Br J Cancer. 2020 Sep;123(7):1047-1059. doi: 10.1038/s41416-020-0987-3. Epub 2020 Jul 22.
2
New Treatment Options for Advanced Biliary Tract Cancer.新型治疗选择用于晚期胆道癌
Curr Treat Options Oncol. 2020 Jun 29;21(8):63. doi: 10.1007/s11864-020-00767-3.
3
Association of Age with Efficacy of Immunotherapy in Metastatic Melanoma.年龄与免疫疗法治疗转移性黑色素瘤疗效的关系。
Oncologist. 2020 Feb;25(2):e381-e385. doi: 10.1634/theoncologist.2019-0377. Epub 2019 Oct 29.
4
Patterns and genomic correlates of PD-L1 expression in patients with biliary tract cancers.胆管癌患者中PD-L1表达的模式及基因组相关性
J Gastrointest Oncol. 2019 Dec;10(6):1099-1109. doi: 10.21037/jgo.2019.08.08.
5
Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study.帕博利珠单抗治疗非结直肠癌高度微卫星不稳定/错配修复缺陷型癌症患者的疗效：来自 II 期 KEYNOTE-158 研究的结果。
J Clin Oncol. 2020 Jan 1;38(1):1-10. doi: 10.1200/JCO.19.02105. Epub 2019 Nov 4.
6
Impact of Patients' Gender on Efficacy of Immunotherapy in Patients With Metastatic Kidney Cancer: A Systematic Review and Meta-analysis.患者性别对转移性肾细胞癌患者免疫治疗疗效的影响：系统评价和荟萃分析。
Clin Genitourin Cancer. 2020 Apr;18(2):88-94.e2. doi: 10.1016/j.clgc.2019.09.004. Epub 2019 Sep 27.
7
Factors Influencing the Efficacy of Anti-PD-1 Therapy in Chinese Patients with Advanced Melanoma.影响中国晚期黑色素瘤患者抗PD-1治疗疗效的因素
J Oncol. 2019 Sep 26;2019:6454989. doi: 10.1155/2019/6454989. eCollection 2019.
8
Molecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targets.胆管癌的分子谱分析揭示了不同的分子改变和潜在的治疗靶点。
J Gastrointest Oncol. 2019 Aug;10(4):652-662. doi: 10.21037/jgo.2018.08.18.
9
Local and abscopal responses in advanced intrahepatic cholangiocarcinoma with low TMB, MSS, pMMR and negative PD-L1 expression following combined therapy of SBRT with PD-1 blockade.局部和远隔效应在低 TMB、MSS、pMMR 和 PD-L1 表达阴性的晚期肝内胆管细胞癌患者中，经 SBRT 联合 PD-1 阻断治疗后的表现。
J Immunother Cancer. 2019 Aug 5;7(1):204. doi: 10.1186/s40425-019-0692-z.
10
Significant benefit of nivolumab combining radiotherapy in metastatic gallbladder cancer patient with strong PD-L1 expression: a case report.纳武单抗联合放疗对PD-L1高表达的转移性胆囊癌患者有显著疗效：一例报告
Onco Targets Ther. 2019 Jul 8;12:5389-5393. doi: 10.2147/OTT.S208926. eCollection 2019.
Zotero 插件